[Role of pemetrexed in the treatment of advanced non-small-cell lung cancer: news from ASCO, 2008]

Tumori. 2008 Sep-Oct;94(5):suppl 3-13.
[Article in Italian]
No abstract available

Publication types

  • Review

MeSH terms

  • Adenocarcinoma / drug therapy
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bevacizumab
  • Carcinoma, Large Cell / drug therapy
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Carcinoma, Non-Small-Cell Lung / prevention & control
  • Carcinoma, Squamous Cell / drug therapy
  • Cisplatin / administration & dosage
  • Clinical Trials as Topic
  • Glutamates / adverse effects
  • Glutamates / therapeutic use*
  • Guanine / adverse effects
  • Guanine / analogs & derivatives*
  • Guanine / therapeutic use
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / pathology
  • Lung Neoplasms / prevention & control
  • Neoplasm Recurrence, Local / prevention & control
  • Pemetrexed
  • Societies, Medical
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Glutamates
  • Pemetrexed
  • Bevacizumab
  • Guanine
  • Cisplatin